GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (FRA:HN30) » Definitions » Shiller PE Ratio

Restart Life Sciences (FRA:HN30) Shiller PE Ratio : (As of May. 04, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Restart Life Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Restart Life Sciences Shiller PE Ratio Historical Data

The historical data trend for Restart Life Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Restart Life Sciences Shiller PE Ratio Chart

Restart Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Restart Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Restart Life Sciences's Shiller PE Ratio

For the Biotechnology subindustry, Restart Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Restart Life Sciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's Shiller PE Ratio falls into.


;
;

Restart Life Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Restart Life Sciences's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Restart Life Sciences's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.007/127.3637*127.3637
=-0.007

Current CPI (Dec. 2024) = 127.3637.

Restart Life Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.293 99.789 -0.374
201506 -0.104 100.500 -0.132
201509 -0.269 100.421 -0.341
201512 -0.268 99.947 -0.342
201603 -0.049 101.054 -0.062
201606 -0.111 102.002 -0.139
201609 -0.103 101.765 -0.129
201612 -0.853 101.449 -1.071
201703 -0.089 102.634 -0.110
201706 -0.106 103.029 -0.131
201709 -0.273 103.345 -0.336
201712 -0.265 103.345 -0.327
201803 -0.502 105.004 -0.609
201806 -0.043 105.557 -0.052
201809 -0.263 105.636 -0.317
201812 0.000 105.399 0.000
201903 -0.066 106.979 -0.079
201906 -0.067 107.690 -0.079
201909 -0.069 107.611 -0.082
201912 0.000 107.769 0.000
202003 -0.065 107.927 -0.077
202006 -1.245 108.401 -1.463
202009 -0.064 108.164 -0.075
202012 -1.043 108.559 -1.224
202103 -0.067 110.298 -0.077
202106 -0.026 111.720 -0.030
202109 -0.067 112.905 -0.076
202112 0.000 113.774 0.000
202203 -0.072 117.646 -0.078
202206 -0.019 120.806 -0.020
202209 -0.021 120.648 -0.022
202212 -0.069 120.964 -0.073
202303 -0.025 122.702 -0.026
202306 -0.014 124.203 -0.014
202309 -0.014 125.230 -0.014
202312 -0.014 125.072 -0.014
202403 -0.007 126.258 -0.007
202406 -0.004 127.522 -0.004
202409 0.027 127.285 0.027
202412 -0.007 127.364 -0.007

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Restart Life Sciences  (FRA:HN30) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Restart Life Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Restart Life Sciences Business Description

Traded in Other Exchanges
Address
700-838 West Hastings St, Vancouver, BC, CAN, V6C 0A6
Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. It is focus is on creating health foods that address the needs of this community. Its Flagship developments includes Autism Spectrum, Health-Related Foods, Psilocybin Clinical Trial for Fragile X Syndrome, Orphan Drug Designation (FDA and EMA).

Restart Life Sciences Headlines

No Headlines